Department of General Surgery, Chengwu People's Hospital Affiliated to Shandong First Medical University, Heze, 274200, Shandong, China.
Department of Gland Surgery, Shandong Provincial Hospital, Jinan, 250021, Shandong, China.
Clin Exp Med. 2021 May;21(2):287-296. doi: 10.1007/s10238-020-00676-7. Epub 2021 Jan 9.
Breast cancer is the most common cancer among women, with metastasis as the principal cause of mortality. MiR-1225 has been reported to play roles in the progression of various cancers, but its role in breast cancer was unclear. The expression of miR-1225 was investigated in breast cancer tissues and cells by quantitative real-time PCR. The role of miR-1225 in the cell process of OS was analyzed by CCK-8 assay and Transwell assay. The prognostic value of miR-1225 was evaluated by Kaplan-Meier survival curves and Cox regression analysis. miR-1225 was significantly upregulated in breast cancer tissues, which was associated with the TNM stage of breast cancer patients. The prognosis of patients with high miR-1225 expression was worse than that of patients with low miR-1225 expression, which indicated that miR-1225 acted as an independent factor for the prognosis of breast cancer. Additionally, the upregulation of miR-1225 promoted cell proliferation, migration, and invasion of breast cancer, which suggested miR-1225 might be involved in the progression of breast cancer. JAK1 was identified as the direct target of miR-1225, which was also involved in cell proliferation, migration, and invasion of breast cancer. The overexpression of miR-1225 in breast cancer indicates a poor prognosis of patients and promotes the progression of breast cancer by targeting JAK1. miR-1225 may be a biomarker and therapeutic target for the treatment of breast cancer.
乳腺癌是女性中最常见的癌症，转移是导致死亡的主要原因。miR-1225 已被报道在各种癌症的进展中发挥作用，但它在乳腺癌中的作用尚不清楚。通过实时定量 PCR 研究了 miR-1225 在乳腺癌组织和细胞中的表达。通过 CCK-8 测定和 Transwell 测定分析了 miR-1225 在 OS 细胞过程中的作用。通过 Kaplan-Meier 生存曲线和 Cox 回归分析评估了 miR-1225 的预后价值。miR-1225 在乳腺癌组织中显著上调，与乳腺癌患者的 TNM 分期有关。高 miR-1225 表达患者的预后比低 miR-1225 表达患者差，表明 miR-1225 是乳腺癌预后的独立因素。此外，miR-1225 的上调促进了乳腺癌细胞的增殖、迁移和侵袭，表明 miR-1225 可能参与了乳腺癌的进展。JAK1 被鉴定为 miR-1225 的直接靶标，它也参与了乳腺癌细胞的增殖、迁移和侵袭。乳腺癌中 miR-1225 的过表达表明患者预后不良，并通过靶向 JAK1 促进乳腺癌的进展。miR-1225 可能是乳腺癌治疗的生物标志物和治疗靶点。
